Introduction There are no disease-modifying treatments for Parkinson’s disease (PD). We undertook the first drug screen in PD patient tissue and idntified ursodeoxycholic acid (UDCA) as a promising mitochondrial rescue agent. The aims of this trial are to determine safety and tolerability of UDCA in PD at 30 mg/kg, confirm the target engagement of UDCA, apply a novel motion sensor-based approach to quantify disease progression objectively, and estimate the mean effect size and its variance on the change in motor severity. Methods and analysis This is a phase II, two-centre, double-blind, randomised, placebo-controlled trial of UDCA at a dose of 30 mg/kg in 30 participants with early PD. Treatment duration is 48 weeks, followed by an 8-we...
Introduction: Parkinson’s Disease (PD) is the second most frequent neurodegenerative disease and dop...
This is the author accepted manuscript.Data Sharing: The PD STAT study protocol and statistical anal...
Parkinson’s Disease (PD) is the most prevalent neurodegenerative disease following Alzheimer’s disea...
Parkinson’s disease (PD) is an incurable neurodegenerative disease of the elderly. Although the prec...
This is the final version. Available from BMJ Publishing via the DOI in this recordINTRODUCTION: Par...
This work is supported by grants from The Cure Parkinson’s Trust and JP Moulton Charitable Foundatio...
Parkinson's disease (PD) is characterized by severe motor symptoms, and currently there is no treatm...
There is strong evidence of a key role for mitochondrial dysfunction in both sporadic and all forms ...
Background: Parkinson’s disease (PD) is a progressive neurodegenerative disease with no cure and few...
INTRODUCTION: Parkinson's disease (PD) is a common neurodegenerative disorder with substantial morbi...
Many agents developed for neuroprotective treatment of Parkinson disease (PD) have shown great promi...
As therapeutic trials target early stages of Parkinson’s disease (PD), appropriate patient selection...
Parkinson’s disease (PD) is a progressive neurodegenerative disorder that currently has no cure, but...
Parkinson's disease (PD) is a progressive neurodegenerative disorder that primarily affects elderly ...
© 2021 Azevedo Kauppila et al. This work is published and licensed by Dove Medical Press Limited. Th...
Introduction: Parkinson’s Disease (PD) is the second most frequent neurodegenerative disease and dop...
This is the author accepted manuscript.Data Sharing: The PD STAT study protocol and statistical anal...
Parkinson’s Disease (PD) is the most prevalent neurodegenerative disease following Alzheimer’s disea...
Parkinson’s disease (PD) is an incurable neurodegenerative disease of the elderly. Although the prec...
This is the final version. Available from BMJ Publishing via the DOI in this recordINTRODUCTION: Par...
This work is supported by grants from The Cure Parkinson’s Trust and JP Moulton Charitable Foundatio...
Parkinson's disease (PD) is characterized by severe motor symptoms, and currently there is no treatm...
There is strong evidence of a key role for mitochondrial dysfunction in both sporadic and all forms ...
Background: Parkinson’s disease (PD) is a progressive neurodegenerative disease with no cure and few...
INTRODUCTION: Parkinson's disease (PD) is a common neurodegenerative disorder with substantial morbi...
Many agents developed for neuroprotective treatment of Parkinson disease (PD) have shown great promi...
As therapeutic trials target early stages of Parkinson’s disease (PD), appropriate patient selection...
Parkinson’s disease (PD) is a progressive neurodegenerative disorder that currently has no cure, but...
Parkinson's disease (PD) is a progressive neurodegenerative disorder that primarily affects elderly ...
© 2021 Azevedo Kauppila et al. This work is published and licensed by Dove Medical Press Limited. Th...
Introduction: Parkinson’s Disease (PD) is the second most frequent neurodegenerative disease and dop...
This is the author accepted manuscript.Data Sharing: The PD STAT study protocol and statistical anal...
Parkinson’s Disease (PD) is the most prevalent neurodegenerative disease following Alzheimer’s disea...